Description
Fragmin Solution for Injections 10000 IU 1ml. №10
Ingredients:
Each 1ml contains 10000 IU of dalteparin sodium as the active ingredient.
Mechanism of Action:
Dalteparin, a low molecular weight heparin, inhibits the formation of blood clots by enhancing the activity of antithrombin III, leading to the inhibition of factor Xa and thrombin.
Pharmacological Properties:
Fragmin exhibits antithrombotic activity by selectively inhibiting factor Xa, thereby preventing the conversion of prothrombin to thrombin and the formation of fibrin clots.
Indications for Use:
- Prevention of deep vein thrombosis (DVT) in patients undergoing surgery
- Treatment of acute DVT and pulmonary embolism
Contraindications:
Do not use Fragmin in patients with:
- Active major bleeding
- History of heparin-induced thrombocytopenia
- Hypersensitivity to dalteparin or heparin
Side Effects:
Common side effects of Fragmin may include bleeding, thrombocytopenia, injection site reactions, and allergic reactions. Patients should be monitored for these adverse effects.
Usage Instructions:
Administer Fragmin subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites and avoid mixing with other injections to prevent interactions.
Benefits Compared to Analogues:
Fragmin offers a more predictable anticoagulant response, reduced risk of heparin-induced thrombocytopenia, and a lower incidence of osteoporosis compared to unfractionated heparin.
Suitable Patient Groups:
Fragmin can be used in various patient populations, including adults, elderly patients, and children under appropriate medical supervision.
Storage and Shelf Life:
Store Fragmin as per the manufacturer’s instructions. Check the expiration date on the packaging and do not use the product beyond the stated shelf life.
Packaging Description:
Fragmin is available in packages containing 10 vials of 1ml solution for injections, each vial containing 10000 IU of dalteparin sodium.
Clinical Evidence and Proven Effectiveness:
Fragmin has been extensively studied in clinical trials, demonstrating its efficacy in reducing the risk of thromboembolic events in surgical and medical patients. Clinical studies have shown that dalteparin is effective in preventing and treating thromboembolic disorders with a favorable safety profile compared to unfractionated heparin.
